Last reviewed · How we verify

Dapivirine Vaginal Ring-004

International Partnership for Microbicides, Inc. · Phase 3 active Small molecule

Dapivirine Vaginal Ring-004 is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) Small molecule drug developed by International Partnership for Microbicides, Inc.. It is currently in Phase 3 development for HIV-1 prevention in women (pre-exposure prophylaxis). Also known as: TMC-120.

Dapivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication when released from a vaginal ring formulation.

Dapivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication when released from a vaginal ring formulation. Used for HIV-1 prevention in women (pre-exposure prophylaxis).

At a glance

Generic nameDapivirine Vaginal Ring-004
Also known asTMC-120
SponsorInternational Partnership for Microbicides, Inc.
Drug classNon-nucleoside reverse transcriptase inhibitor (NNRTI)
TargetHIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhasePhase 3

Mechanism of action

Dapivirine inhibits HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and integrating into host cells. The vaginal ring formulation provides sustained local and systemic drug delivery over several weeks, offering long-acting HIV prevention. This approach aims to provide women with a discreet, user-controlled contraceptive-like method for HIV pre-exposure prophylaxis (PrEP).

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dapivirine Vaginal Ring-004

What is Dapivirine Vaginal Ring-004?

Dapivirine Vaginal Ring-004 is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) drug developed by International Partnership for Microbicides, Inc., indicated for HIV-1 prevention in women (pre-exposure prophylaxis).

How does Dapivirine Vaginal Ring-004 work?

Dapivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication when released from a vaginal ring formulation.

What is Dapivirine Vaginal Ring-004 used for?

Dapivirine Vaginal Ring-004 is indicated for HIV-1 prevention in women (pre-exposure prophylaxis).

Who makes Dapivirine Vaginal Ring-004?

Dapivirine Vaginal Ring-004 is developed by International Partnership for Microbicides, Inc. (see full International Partnership for Microbicides, Inc. pipeline at /company/international-partnership-for-microbicides-inc).

Is Dapivirine Vaginal Ring-004 also known as anything else?

Dapivirine Vaginal Ring-004 is also known as TMC-120.

What drug class is Dapivirine Vaginal Ring-004 in?

Dapivirine Vaginal Ring-004 belongs to the Non-nucleoside reverse transcriptase inhibitor (NNRTI) class. See all Non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs at /class/non-nucleoside-reverse-transcriptase-inhibitor-nnrti.

What development phase is Dapivirine Vaginal Ring-004 in?

Dapivirine Vaginal Ring-004 is in Phase 3.

What are the side effects of Dapivirine Vaginal Ring-004?

Common side effects of Dapivirine Vaginal Ring-004 include Vaginal irritation or discomfort, Headache, Vulvovaginal candidiasis, Abnormal vaginal discharge.

What does Dapivirine Vaginal Ring-004 target?

Dapivirine Vaginal Ring-004 targets HIV reverse transcriptase and is a Non-nucleoside reverse transcriptase inhibitor (NNRTI).

Related